The joumal uses Crossref ited-by service counts times cited of published aricles. Citedby allows Crossref members to find out who is citing their conten. This is the Citing Article List of "“Targeting HER2 in breast cancer: new drugs and paradigms on the horizon”.
|
No. |
Publication Date |
Citing Article |
|
1 |
2022 |
Rossella Loria, Patrizia Vici, Francesca Sofia Di Lisa, Silvia Soddu, Marcello Maugeri-Saccà, Giulia Bon. Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue, Frontiers in Oncology. 2022; 12: 877380. https://doi.org/10.3389/fonc.2022.877380 |
|
2 |
2024 |
Parastoo Shahrouzi, Youness Azimzade, Wioletta Brankiewicz, Sugandha Bhatia, David Kunke, Derek Richard, Xavier Tekpli, Vessela N. Kristensen, Pascal H.G. Duijf. 2024; https://doi.org/10.21203/rs.3.rs-4594599/v1 |
|
3 |
2024 |
Soo-Yeon Hwang, Kyung-Hwa Jeon, Hwa-Jong Lee, Inhye Moon, Sehyun Jung, Seul-Ah Kim, Hyunji Jo, Seojeong Park, Misun Ahn, Soo-Yeon Kwak, Younghwa Na, Youngjoo Kwon. 2024; https://doi.org/10.7554/eLife.97051.1 |
|
4 |
2024 |
Parastoo Shahrouzi, Youness Azimzade, Wioletta Brankiewicz, Sugandha Bhatia, David Kunke, Derek Richard, Xavier Tekpli, Vessela N. Kristensen, Pascal H.G. Duijf. 2024; https://doi.org/10.1101/2024.06.18.599481 |
|
5 |
2024 |
Soo-Yeon Hwang, Kyung-Hwa Jeon, Hwa-Jong Lee, Inhye Moon, Sehyun Jung, Seul-Ah Kim, Hyunji Jo, Seojeong Park, Misun Ahn, Soo-Yeon Kwak, Younghwa Na, Youngjoo Kwon. 2024; https://doi.org/10.1101/2024.03.01.583029 |
|
6 |
2025 |
Warisha Kanwal, Kaneez Narjis, Sarah Musani, Fnu Nancy, Laiba Qureshi, Muhammad Mudasir, Rohma Naseem, Fnu Tooba, Juvairia Yousuf, Kanza Farhan, Hadiya Javed, Mohammed Mahmmoud Fadelallah Eljack. Exploring Zanidatamab’s efficacy across HER2-positive Malignancies: a narrative review, BMC Cancer. 2025; 25: 382. https://doi.org/10.1186/s12885-025-13749-1 |
|
7 |
2024 |
Soo-Yeon Hwang, Kyung-Hwa Jeon, Hwa-Jong Lee, Inhye Moon, Sehyun Jung, Seul-Ah Kim, Hyunji Jo, Seojeong Park, Misun Ahn, Soo-Yeon Kwak, Younghwa Na, Youngjoo Kwon. 2024; https://doi.org/10.7554/eLife.97051.2 |
|
8 |
2024 |
Luying Xu, Yuxin Xie, Qiheng Gou, Rui Cai, Rong Bao, Yucheng Huang, Ruisi Tang. HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future, Frontiers in Pharmacology. 2024; 15: 1446414. https://doi.org/10.3389/fphar.2024.1446414 |
|
9 |
2024 |
Soo-Yeon Hwang, Kyung-Hwa Jeon, Hwa-Jong Lee, Inhye Moon, Sehyun Jung, Seul-Ah Kim, Hyunji Jo, Seojeong Park, Misun Ahn, Soo-Yeon Kwak, Younghwa Na, Youngjoo Kwon. Synthesis and biological assessment of chalcone and pyrazoline derivatives as novel inhibitor for ELF3-MED23 interaction, eLife. 2024; 13: RP97051. https://doi.org/10.7554/eLife.97051 |
|
10 |
2024 |
Soo-Yeon Hwang, Kyung-Hwa Jeon, Hwa-Jong Lee, Inhye Moon, Sehyun Jung, Seul-Ah Kim, Hyunji Jo, Seojeong Park, Misun Ahn, Soo-Yeon Kwak, Younghwa Na, Youngjoo Kwon. Synthesis and biological assessment of chalcone and pyrazoline derivatives as novel inhibitor for ELF3-MED23 interaction, eLife. 2024; 13: RP97051. https://doi.org/10.7554/eLife.97051.3 |